OBJECTIVE: To estimate the prevalence and characteristics of long-term nonprogressor (LTNP) and HIV controller patients in a very large French cohort of HIV1-infected patients. METHODS: In the French Hospital Database on HIV [FHDH, Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) CO4], we selected patients who had been seen in 2005, who had been infected for more than 8 years, who were treatment-naive, and who remained asymptomatic. Patients with these characteristics then categorized as follows: LTNP (> or =8 years of HIV infection and CD4 cell nadir > or =500/microl), elite LTNP (> or =8 years of HIV infection, CD4 cell nadir > or =600/microl, and a positive CD4 slope), HIV controllers (>10 years of HIV infection with 90% of plasma viral load values < or =500 copies/ml), and elite controllers (same as HIV controllers, but with last plasma viral load value < or =50 copies/ml in 2005). RESULTS: Among the 46 880 HIV1-infected patients followed in 2005 in the French Hospital Database on HIV, 0.4% (N = 202) were LTNP, 0.05% (N = 25) were elite LTNP, 0.22% (N = 101) were HIV controllers, and 0.15% (N = 69) were elite controllers. Ten elite LTNP patients (40%) were also HIV controllers, eight (32%) were elite controllers, and 60% had detectable plasma viral load (>50 copies/ml). Among the elite controllers, 32 (46%) were LTNP, eight (12%) were elite LTNP, and one-quarter had a last CD4 cell count less than 500/microl. CONCLUSION: LTNP, elite LTNP, HIV controller, and elite controller patients are rare phenotypes. Elite LTNP patients are less frequent than HIV controllers. There is little overlap among the four subgroups of patients.
OBJECTIVE: To estimate the prevalence and characteristics of long-term nonprogressor (LTNP) and HIV controller patients in a very large French cohort of HIV1-infectedpatients. METHODS: In the French Hospital Database on HIV [FHDH, Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) CO4], we selected patients who had been seen in 2005, who had been infected for more than 8 years, who were treatment-naive, and who remained asymptomatic. Patients with these characteristics then categorized as follows: LTNP (> or =8 years of HIV infection and CD4 cell nadir > or =500/microl), elite LTNP (> or =8 years of HIV infection, CD4 cell nadir > or =600/microl, and a positive CD4 slope), HIV controllers (>10 years of HIV infection with 90% of plasma viral load values < or =500 copies/ml), and elite controllers (same as HIV controllers, but with last plasma viral load value < or =50 copies/ml in 2005). RESULTS: Among the 46 880 HIV1-infectedpatients followed in 2005 in the French Hospital Database on HIV, 0.4% (N = 202) were LTNP, 0.05% (N = 25) were elite LTNP, 0.22% (N = 101) were HIV controllers, and 0.15% (N = 69) were elite controllers. Ten elite LTNP patients (40%) were also HIV controllers, eight (32%) were elite controllers, and 60% had detectable plasma viral load (>50 copies/ml). Among the elite controllers, 32 (46%) were LTNP, eight (12%) were elite LTNP, and one-quarter had a last CD4 cell count less than 500/microl. CONCLUSION: LTNP, elite LTNP, HIV controller, and elite controller patients are rare phenotypes. Elite LTNP patients are less frequent than HIV controllers. There is little overlap among the four subgroups of patients.
Authors: Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson Journal: J Virol Date: 2010-05-05 Impact factor: 5.103
Authors: Kevin O Saunders; Cavin Ward-Caviness; Robert J Schutte; Stephanie A Freel; R Glenn Overman; Nathan M Thielman; Coleen K Cunningham; Thomas B Kepler; Georgia D Tomaras Journal: Cell Immunol Date: 2010-10-27 Impact factor: 4.868
Authors: Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: Philomena Kamya; Christos M Tsoukas; Salix Boulet; Jean-Pierre Routy; Réjean Thomas; Pierre Côté; Mohamed-Rachid Boulassel; Bernard Lessard; Rupert Kaul; Mario Ostrowski; Colin Kovacs; Cecile L Tremblay; Nicole F Bernard Journal: AIDS Res Ther Date: 2011-06-16 Impact factor: 2.250
Authors: Kevin O Saunders; Stephanie A Freel; R Glenn Overman; Coleen K Cunningham; Georgia D Tomaras Journal: Virology Date: 2010-07-01 Impact factor: 3.616